This IMAP statement serves as a reminder of this call to action to ensure all people have access to comprehensive SRH services, including integrated contraceptive and HIV/STI services, provided through primary healthcare.
Following the following the release of the result of the ECHO trial and the WHO latest guidance statement and revised Medical Eligibility Criteria (MEC) for contraceptive use, IPPF developed a follow-up technical brief to support IPPF MAs and frontline service providers’ work regarding the provision of the integrated contraceptive, HIV and other STI programmes to expand access and contraceptive choice.
IPPF attended World Water Week Conference in Stockholm on 28-29 August and presented a reportthat we prepared together with WaterAid, MSI, IWHC and Simavi which demonstrates that combining WASH and SRHR bolsters health and human rights outcomes.
The Advocacy Common Agenda will guide our work at all levels of the Federation to achieve Outcome 1 of the IPPF Strategic Framework 2016–2022, namely to ensure that 100 governments respect, protect and fulfil sexual and reproductive rights and gender equality. In doing so, IPPF will contribute to the International Conference on Population and Development Programme of Action, and to the Sustainable Development Goals.
IPPF is committed to the achievement of gender equality because it is a human right, it advances women’s and girls’ empowerment and it is embedded in sexual and reproductive health and rights (SRHR). As such, we are proud to present a gender equality toolkit for Member Associations.
The historically mixed data and the need to control for confounding required further investigation into the association between use of progestogen‑only injectables and increased risk of HIV acquisition, using a more robust research design. This led to the development of the Evidence for Contraceptive Options and HIV Outcomes (ECHO) trial.
The results of the ECHO trial were published in the Lancet on 13 June 2019. The ECHO trial finds no link between HIV acquisition and the use of DMPA-IM, progestogen implant, and non-hormonal copper IUD.